文献速递神经肿瘤小儿神经外科与脑积水

接受放疗的儿童低级别胶质瘤与胶质神经元肿瘤的风险分层:一项整合临床病理与分子特征的分析

Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis.
PubMed 文献 · Neuro Oncol · 2020-01-01

本研究纳入1997至2017年单中心150例不可切除、非转移性儿童低级别胶质瘤/胶质神经元肿瘤(LGG/LGGNT)放疗患者,用递归分割分析(RPA)按总生存(OS)分层并在CNS9702数据(n=48)中验证;高风险组(弥漫性星形细胞瘤或丘脑/中脑定位)10年OS为76.4%,低风险组为95.6%(P=0.003)。

要点

  • 高风险定义为弥漫性星形细胞瘤组织学或丘脑/中脑定位,低风险为丘脑/中脑外的毛细胞型星形细胞瘤/节细胞胶质瘤。
  • RPA分层低风险组10年OS 95.6% vs 高风险组76.4%(P=0.003),并在CNS9702数据中验证。
  • 高风险组中延迟放疗(至少一线化疗后)与总生存进一步下降相关(P=0.021)。

核心结论

  • 由弥漫性星形细胞瘤组织学或中脑/丘脑肿瘤定位定义的高风险亚组长期生存欠佳,可能获益于及时使用放疗;这些结果需要验证。

研究设计与样本

  • 单中心1997至2017年纳入150例非转移性、活检证实的不可切除LGG/LGGNT接受放疗的儿童,中位随访11.4年,采用递归分割分析(RPA)按总生存分层,并用CNS9702数据(n=48)验证。

主要发现

  • RPA得出低风险组与高风险组10年OS分别为95.6%与76.4%(95%CI:88.7%-98.4% vs 59.3%-87.1%,P=0.003)。
  • CNS9702数据集(n=48)验证:低风险组 vs 高风险组4年OS为100% vs 64%(P<0.001)。
  • 高风险肿瘤包括弥漫性星形细胞瘤或位于丘脑/中脑;低风险肿瘤包括位于丘脑/中脑外的毛细胞型星形细胞瘤/节细胞胶质瘤。
  • 在已知BRAF状态的亚组(n=49)中,风险分层独立于BRAF改变(V600E或融合)仍具预后意义。
  • 高风险组中,延迟放疗(定义为至少一线化疗后放疗)与总生存进一步下降相关(P=0.021)。

关键数值与推荐

  • 高风险:弥漫性星形细胞瘤组织学或丘脑/中脑定位;低风险:丘脑/中脑外的毛细胞型星形细胞瘤/节细胞胶质瘤。
  • 低风险组 vs 高风险组10年OS:95.6% vs 76.4%(95%CI:88.7%-98.4% vs 59.3%-87.1%,P=0.003)。
  • CNS9702验证队列低风险组 vs 高风险组4年OS:100% vs 64%(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些结果需要验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of unresectable pediatric low-grade glioma and glioneuronal tumor (LGG/LGGNT) is controversial. There are no validated prognostic features to guide use of radiation therapy (RT). Our study aimed to identify negative prognostic features in patients treated with RT using clinicopathologic and molecular data and validate these findings in an external dataset. METHODS: Children with non-metastatic, biopsy-proven unresectable LGG/LGGNT treated with RT at a single institution between 1997 and 2017 were identified. Recursive partitioning analysis (RPA) was used to stratify patients into low- and high-risk prognostic groups based on overall survival (OS). CNS9702 data were used for validation. RESULTS: One hundred and fifty patients met inclusion criteria. Median follow-up was 11.4 years. RPA yielded low- and high-risk groups with 10-year OS of 95.6% versus 76.4% (95% CI: 88.7%-98.4% vs 59.3%-87.1%, P = 0.003), respectively. These risk groups were validated using CNS9702 dataset (n = 48) (4-year OS: low-risk vs high-risk: 100% vs 64%, P < 0.001). High-risk tumors included diffuse astrocytoma or location within thalamus/midbrain. Low-risk tumors included pilocytic astrocytoma/ganglioglioma located outside of the thalamus/midbrain. In the subgroup with known BRAF status (n = 49), risk stratification remained prognostic independently of BRAF alteration (V600E or fusion). Within the high-risk group, delayed RT, defined as RT after at least one line of chemotherapy, was associated with a further decrement in overall survival (P = 0.021). CONCLUSION: A high-risk subgroup of patients, defined by diffuse astrocytoma histology or midbrain/thalamus tumor location, have suboptimal long-term survival and might benefit from timely use of RT. These results require validation.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Acharya S, Liu JF, Tatevossian RG, et al. Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro Oncol. 2020. PMID: 32052049. doi:10.1093/neuonc/noaa031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。